International Partnership of Foundations Invests in Drug Development for Neurodegenerative Diseases

An international collaboration of medical charities and foundations led by MRC Technology will invest over £30 million (~$47 million) into developing therapies for brain diseases. The initiative, called Neurodegeneration Medicines Acceleration Programme (Neuro-MAP) will focus on developing promising new therapies for ALS and other neurodegenerative diseases by repurposing approved drugs or testing drug candidates previously shelved by pharmaceutical companies. Promising candidates will be delivered back to pharmaceutical companies for later stage development.

An international collaboration of medical charities and foundations led by MRC Technology will invest over £30 million (~$47 million) into developing therapies for brain diseases. The initiative, called Neurodegeneration Medicines Acceleration Programme (Neuro-MAP) will focus on developing promising new therapies for ALS and other neurodegenerative diseases by repurposing approved drugs or testing drug candidates previously shelved by pharmaceutical companies. Promising candidates will be delivered back to pharmaceutical companies for later stage development.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail